National Centre for Antimicrobial Stewardship - Human and animal. Innovation, implementation, technology and data science! Tweets by Prof Karin (Kas) Thursky.
Melbourne, Australia
Joined April 2015
- Tweets9K
- Following1.3K
- Followers3.8K
- Likes12.2K
NCAS_Australia retweeted
The best clinical resources start with conversations.
At #MM2026 we're looking forward to connecting with pharmacists, hearing about the challenges you’re facing, and discussing how trusted medicines information can support practice. Come and say hello to our team at Booth 40.
NCAS_Australia retweeted
The 1st of 2 new articles in CID critical of clinical guideline process is out. See
academic.oup.com/cid/article…
It is long past time clinical guidelines incorporate the humility of uncertainty & stop creating standards of care absent of reproducible prospective studies.
@ABsteward
NCAS_Australia retweeted
Prior Antibiotic Exposure and Subsequent Resistance in the Individual Patient
🆕💥🔴Progressing From Association to Causation: Examining Prior Antibiotic Exposure and Antimicrobial Resistance Across 3 US Health Systems Using Causal Machine Learning
Prior antibiotic exposure was consistently associated with increased same-class nonsusceptibility across antibiotic classes and health systems, paralleling higher rates of microbiologically inactive empiric therapy #idxposts academic.oup.com/cid/article…
NCAS_Australia retweeted
JAMA actualiza sus recomendaciones sobre el uso de inteligencia artificial por los autores
Lo resumo en mi entrada de #BiblioGetafe:
bibliogetafe.com/2026/09/24/…
NCAS_Australia retweeted
The Lancet staff are going on strike for the first time in the journal’s 200-year history.
Is it surprising? I don’t think so.
Authors produce the research and write the papers. Reviewers provide scientific evaluation, mostly for free. Editors carry much of the burden of keeping the system running. Then the same academic community pays thousands of dollars in APCs to make its own work open access.
Yet staff are now striking over pay, while the publisher’s scientific, technical and medical division reports more than £1 billion in annual adjusted operating profit.
So there is a simple question: where does all that money go?
Authors, reviewers, editors, and institutions are carrying an ever-growing burden. I don’t think the current academic publishing model is sustainable.
researchprofessionalnews.com…
NCAS_Australia retweeted
🤖🩺 ¿Cómo debe un médico utilizar la Inteligencia Artificial sin comprometer la seguridad del paciente 🛡️ ni asumir riesgos legales innecesarios? ⚖️🏥✨
📄 El nuevo artículo de opinión de The BMJ, escrito por el especialista en ética médica Daniel Sokol, propone 6 reglas para integrar la IA de forma segura y responsable en la práctica clínica 👇🤖
1️⃣🧠🛠️ Usa la herramienta adecuada y compréndela: conoce sus objetivos 🎯, funcionamiento y limitaciones ⚠️ antes de aplicarla.
2️⃣🔒🧑⚕️ Protege la confidencialidad: nunca introduzcas datos identificables de pacientes 👤📋 en sistemas de IA no autorizados 🚫.
3️⃣🔍✅ Verifica los datos de entrada y salida: incluso una IA fiable puede equivocarse ⚠️. El juicio clínico 🩺🧠 sigue siendo esencial.
4️⃣🗣️🤝 Informa al paciente cuando sea relevante: especialmente si el uso de IA puede afectar de forma material al diagnóstico 🔬, pronóstico 📈 o tratamiento 💊.
5️⃣📝📂 Deja un registro útil: documenta cómo influyó la IA en la decisión clínica y explica tus motivos, especialmente si te apartas de su recomendación 🤖↔️👨⚕️.
6️⃣🚨🛡️ Actúa ante errores: si la IA produce un resultado potencialmente inseguro, protege al paciente ❤️🩹, informa del incidente 📢 e identifica el sistema y su versión cuando sea posible.
💡🔎 Sería interesante complementar estas recomendaciones con protocolos institucionales de auditoría 📊🏥 para monitorizar sesgos algorítmicos ⚖️🤖 y otros riesgos durante el uso clínico real.
🎯 La IA debe servir para ofrecer una atención mejor y más segura para los pacientes 🩺❤️🤖.
#InteligenciaArtificial #IA #SaludDigital #ÉticaMédica #SeguridadDelPaciente #InnovaciónSanitaria #Medicina
🔗👇🏻 doi.org/10.1136/bmj-2026-100…
NCAS_Australia retweeted
In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months. Full SOLARIO trial results: nej.md/4dgrqwY
ALT This image shows a forest plot showing the robustness of the primary analysis results. Subgroups include definite treatment failure, definite or probable treatment failure, and definite, probable, or possible treatment failure. Hazard ratios with 95% confidence intervals are displayed, indicating whether a short duration is better than a long duration. A red line indicates the noninferiority margin.
A longstanding issue impacting on our clinical guidelines for neutropenic fever empiric therapy for adults. The reason? PKPD? MICs of pathogens? Neurotoxicity? Unlikely to see a prospective RCT (although the @snap_trial team might be interested)
Finally it's published!
🆕🔥🟢Systematic Review and Bayesian Meta-Analysis @DrToddLee
What is the association of cefepime with all-cause mortality compared with other β-lactam antibiotics?
This systematic review and bayesian meta-analysis found that cefepime was associated with higher odds of all-cause mortality compared with other β-lactams Meta-analysis of published peer-reviewed RCTs (73 trials, 15 411 patients) showed that cefepime was associated with a 98.6% posterior probability of higher mortality compared with other β-lactams (OR, 1.17; 95% credible interval, 1.02-1.34). Posterior distributions generally favored higher odds of mortality across all comparator β-lactams, across all clinical indications, and with doses of 2 g or more every 12 hours. #idxposts jamanetwork.com/journals/jam…
NCAS_Australia retweeted
Finally it's published!
🆕🔥🟢Systematic Review and Bayesian Meta-Analysis @DrToddLee
What is the association of cefepime with all-cause mortality compared with other β-lactam antibiotics?
This systematic review and bayesian meta-analysis found that cefepime was associated with higher odds of all-cause mortality compared with other β-lactams Meta-analysis of published peer-reviewed RCTs (73 trials, 15 411 patients) showed that cefepime was associated with a 98.6% posterior probability of higher mortality compared with other β-lactams (OR, 1.17; 95% credible interval, 1.02-1.34). Posterior distributions generally favored higher odds of mortality across all comparator β-lactams, across all clinical indications, and with doses of 2 g or more every 12 hours. #idxposts jamanetwork.com/journals/jam…
NCAS_Australia retweeted
What about the 2 deaths of children who underwent genome editing in China, each not disclosed until a year later, apparently related to viral vector toxicity?
@TheLancet editorial
thelancet.com/journals/lance…
Antibacterial prophylaxis in neutropenic fever: beyond fluoroquinolones sciencedirect.com/science/ar…
NCAS_Australia retweeted
9/ Let me close the way I always do — as the honest doctor, not the hype man, because you deserve both the awe and the truth in the same breath.
Most of what I just described is early. The personalized cancer vaccine is the furthest along, with a real Phase 3 win — but even it still owes us overall-survival data and the full statistical picture. The genetic cholesterol therapy is dazzling in monkeys and has not yet been proven in a single human being. The AI-designed proteins are brilliant first steps that still face the long, brutal road of becoming actual approved drugs. Hype runs ahead of proof in this field constantly, and I will always be the first to tell you when it does. Some of these will stumble. That's how science works.
But here is what is no longer in question: the direction. The wall between "average medicine" and "medicine built for you" has cracked, and it will not un-crack. The tools that saved the world from a virus are now turned toward the diseases that take the most of us, and for the first time the early data says they can win.
I got into medicine to fight these exact enemies, and for most of my career the fight felt like holding a line. This week, for the first time, it felt like advancing. The horizon didn't just brighten — it moved.
What a time to be alive. And what a time to be a doctor.
NCAS_Australia retweeted
A systematic review and meta-analysis evaluating the impact of nudging in microbiology reports on antimicrobial use and clinical outcomes:
clinicalmicrobiologyandinfec…
